Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.

Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.

PURPOSE: We tested the hypothesis that expression of microRNAs (miRNAs) in cancer tissue can predict effectiveness of bevacizumab added to capecitabine and oxaliplatin (CAPEOX) in patients with metastatic colorectal cancer (mCRC). EXPERIMENTAL DESIGN: Patients with mCRC treated with first line CAPEO...

Full description

Bibliographic Details
Main Authors: Mogens K Boisen, Christian Dehlendorff, Dorte Linnemann, Boye S Nielsen, Jim S Larsen, Kell Osterlind, Svend E Nielsen, Line S Tarpgaard, Camilla Qvortrup, Per Pfeiffer, Niels H Holländer, Nina Keldsen, Torben F Hansen, Brita B Jensen, Estrid V S Høgdall, Benny V Jensen, Julia S Johansen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4198118?pdf=render

Internet

http://europepmc.org/articles/PMC4198118?pdf=render

Similar Items